Cadrenal Therapeutics, Inc., (NASDAQ:CVKD) a biopharmaceutical company focused on developing tecarfarin, a late-stage novel cardiorenal therapy with orphan drug and Fast Track designations, today provided a
Increased 2024 GuidanceCompleted the acquisition of CSI on April 1, 2024, creating the industry's largest contract compression fleetRaised full-year 2024 Adjusted EBITDA guidance to a range of $580 to $610 millionExpect